Chronoscale Holdings Corp quarterly report, Q1 FY2019

Business context and reporting period

The filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2019; this differs from the company name in the request metadata. Ekso designs and sells exoskeletons for medical rehabilitation (EksoHealth) and industrial use (EksoWorks). All dollar amounts below are in millions unless stated otherwise.

Financial results and position

  • Revenue: $3.616, up 44% from $2.518 in Q1 2018. EksoHealth revenue was $2.814 (prior year $2.122); EksoWorks was $0.802 (prior year $0.396).
  • Gross profit and margin: Gross profit was $1.599 versus $0.767; gross margin was about 44% versus 30%. Management attributed the increase mainly to higher volume and average selling prices for EksoHealth devices.
  • Operating expenses: $6.511, down 31% from $9.380. Sales and marketing fell 27%, R&D fell 23%, and G&A fell 38%, reflecting lower headcount and other costs, and the absence of prior-year CEO severance and intangible-asset amortization.
  • Losses: Operating loss was $4.912 versus $8.613. Net loss was $6.551 versus $7.901; basic and diluted loss per share was $0.10 versus $0.13.
  • Cash flow: Operating cash use was $5.177, compared with $6.745 in Q1 2018. Investing cash use was $0.007. Financing provided $6.769, including $2.3 from the at-the-market offering and $5.0 from the China JV-related share purchase, offset partly by debt principal payments.
  • Cash and liquidity: Cash was $9.236 at March 31, 2019, up from $7.655 at year-end. The debt covenant required $4.908 of cash to be maintained; management estimated unrestricted cash at $4.328. Current assets were $16.835 and current liabilities $9.710.
  • Debt and obligations: Net long-term debt carrying value was $4.426, including $2.333 current and $2.093 non-current; the loan matures January 2021. Contractual obligations totaled $7.898, including term loan, operating leases, purchase obligations and financing lease payments.
  • Equity and leases: Common shares outstanding rose to 67.529 million from 62.963 million at year-end. Adoption of lease accounting added $1.365 of right-of-use assets and $1.412 of lease liabilities at quarter-end.

Material changes versus the prior comparable period

Revenue and gross profit increased substantially, while operating expenses and operating cash use declined. Net loss improved despite $1.122 of warrant revaluation loss and $0.257 of loss from modifying warrants; Q1 2018 included a $0.732 warrant revaluation gain. The 2015 warrant exercise price was reduced from $3.74 to $2.75. The company issued shares through its ATM program and sold $5.0 of shares to a China JV partner affiliate.

Outlook, risks and contingencies

  • Going concern: The company reported substantial doubt about its ability to continue as a going concern. It said existing resources were expected to cover obligations only until late Q2 2019 and would not fund operations for the next 12 months. It was pursuing additional equity, debt and collaboration financing; availability and terms were not assured. Further cost reductions or curtailed operations could be necessary, and equity financing could dilute shareholders.
  • China JV: The venture is intended to develop Asian markets and establish a manufacturing center. A further $5.0 equity investment is conditional on shipment of first products. An April 30 amendment changed the timing and amount of JV partner capital contributions. The company expects a 20% interest in exchange for transferring technology licenses and patent rights, subject to completing the transfer within one year.
  • Regulatory exposure: The Department of Defense inquired about export-control classification and possible CFIUS review. The company believes the transaction is compliant and outside CFIUS review, but government review, mitigation, restrictions or delay could impair the JV or require it to be unwound.
  • Other risks and contingencies: Risks include financing needs, medical-device regulatory approval, clinical trial and commercialization execution, customer adoption, competition, long sales cycles, foreign-exchange exposure and intellectual-property protection. Purchase obligations were $1.221, primarily due within one year. Management considered pending shareholder derivative litigation without merit and intended to defend it.
  • Guidance: The filing gives no specific revenue, earnings or cash-flow guidance. Management described plans to invest in rehabilitation-market clinical and sales initiatives and continue industrial product development, while pursuing alternative sales channels for EksoVest and EksoZeroG.

Important facts for investors to verify

  • Whether the company obtained sufficient financing after the filing date, and whether its going-concern position changed.
  • Whether the conditional additional $5.0 JV investment was funded and whether technology transfer, manufacturing and sales milestones were achieved.
  • Any developments in CFIUS or export-control review affecting the China JV or technology transfer.
  • Subsequent cash burn, covenant cash requirements, debt payments and actual unrestricted liquidity.
  • Sales growth, margins and unit economics by EksoHealth and EksoWorks, including the conversion of rentals to sales.
  • Potential dilution from further equity issuance and the financial effect of warrant revaluation or modification.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.